Funding Wizard

Identify multi-level solutions for patients on long-term opioid treatment who are exhibiting harmful opioid behaviors, but do not meet criteria for OUD. Patients with lived experience should consult on these projects. A resource center is also needed to clinically identify this ambiguous population and provide metrics for the field for balanced assessment of opioid risks and harms. The resource center would convene a panel of stakeholders and bioethicists to guide these efforts.

Identify multi-level solutions for patients on long-term opioid treatment who are exhibiting harmful opioid behaviors, but do not meet criteria for OUD. Patients with lived experience should consult on these projects. A resource center is also needed to clinically identify this ambiguous population and provide metrics for the field for balanced assessment of opioid risks and harms. The resource center would convene a panel of stakeholders and bioethicists to guide these efforts. NEPS Concept# 2393

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.

The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, multi-component applications proposing the use of omics technologies to advance preventative and/or therapeutic vaccinations, and/or immunomodulatory cure interventions for HIV. Projects will integrate omics, computational, and hypothesis-driven experimental approaches to interrogate immune responses to HIV vaccination and/or cure strategies.

The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious variant of the protein that forces the conformational change. Once this process is initiated, it becomes self-propagating until toxic aggregates accumulate within the CNS, leading to neuronal death. Because misfolded proteins of AD/ADRD have been reported to share some features with pathological prion protein at the structural level, it has thus been proposed that ADRD-relevant proteins such as Alpha, tau, beta-synuclein, and TDP-43 (among others) may exhibit prion-like behaviors that lead to toxic aggregate and tangle formation. The goal of this initiative is to promote studies that increase our understanding of the cellular and molecular mechanisms by which such prion-like conversion events occur and are propagated in AD/ADRD, as well as the downstream mechanisms that trigger neurotoxicity, pathological and circuit changes in the brain.

Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to continue support for the Cancer Immune Monitoring and Analysis Centers Cancer Immunologic Data Center (CIMAC-CIDC) Network. The CIMAC-CIDC is a network of laboratories (CIMACs) and a bioinformatics center (CIDC) established to perform correlative studies using biospecimens from cancer immunotherapy clinical trials. Applying a comprehensive set of state-of-the-art immunoprofiling assays and bioinformatics pipelines, the CIMAC studies encompass genomics, transcriptomics, proteomics, microbiomes, and phenotyping analyses of tumor, tumor microenvironment, blood, stool, and other types of biospecimens. The ultimate goal of the CIMAC-CIDC Network is to identify biomarkers of response, resistance, and adverse events to optimize immunotherapy approaches for patients with cancer. CIMACs work with clinical trial teams and CIDC on correlative studies examining the association of biomarker data from the assays with clinical data from the trials.

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for a Coordinating Center for the Cancer Adoptive Cellular Therapy (Can-ACT) network. The Can-ACT network of research sites will advance collaborative and novel approaches for adoptive cell therapy for solid tumors, with an emphasis on the transition from preclinical testing and translational studies to early phase clinical trials. The Coordinating Center will provide leadership to the Can-ACT network, facilitate data sharing and collaboration, and coordinate clinical trial activities between research sites and the NCI.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for multi-component projects that will investigate the impact of climate change on emerging public health threats associated with marine and Great Lakes Basin environments. The focus of the program will be to support research on the exposures, toxicities and human health impacts that arise in these environments and how climate change is influencing these factors now and in the future. The FOA solicits applications that will achieve program goals through integrated, multidisciplinary scientific approaches and a community engagement component.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.